Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,454 GBX | 0.00% | 0.00% | 0.00% |
24/06 | European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading | MT |
24/06 | British American Tobacco agrees to buy back shares from UBS | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 3.42 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Tobacco
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 73.4B | - | ||
+8.38% | 159B | B- | ||
+44.77% | 7.74B | B- | ||
+104.30% | 2.75B | - | C+ | |
-1.02% | 1.81B | - | ||
-4.26% | 1.7B | - | D+ | |
-28.64% | 1.18B | - | B+ | |
0.00% | 646M | - | - | |
+23.33% | 572M | C+ | ||
-40.40% | 408M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BATS Stock
- BATS Stock
- Ratings British American Tobacco Plc